- Home
- CRDF vs FNWD Comparison
CRDF vs FNWD Comparison
Compare CRDF & FNWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- FNWD
- Stock Information
- Founded
- CRDF 1999
- FNWD 1994
- Country
- CRDF United States
- FNWD United States
- Employees
- CRDF N/A
- FNWD N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- FNWD Savings Institutions
- Sector
- CRDF Health Care
- FNWD Finance
- Exchange
- CRDF Nasdaq
- FNWD Nasdaq
- Market Cap
- CRDF 133.5M
- FNWD 137.4M
- IPO Year
- CRDF N/A
- FNWD N/A
- Fundamental
- Price
- CRDF $4.96
- FNWD $30.48
- Analyst Decision
- CRDF Strong Buy
- FNWD
- Analyst Count
- CRDF 3
- FNWD 0
- Target Price
- CRDF $10.33
- FNWD N/A
- AVG Volume (30 Days)
- CRDF 3.9M
- FNWD 3.8K
- Earning Date
- CRDF 11-07-2024
- FNWD 01-28-2025
- Dividend Yield
- CRDF N/A
- FNWD 1.57%
- EPS Growth
- CRDF N/A
- FNWD 7.22
- EPS
- CRDF N/A
- FNWD 2.71
- Revenue
- CRDF $688,000.00
- FNWD $69,627,000.00
- Revenue This Year
- CRDF $23.78
- FNWD N/A
- Revenue Next Year
- CRDF N/A
- FNWD $1.34
- P/E Ratio
- CRDF N/A
- FNWD $11.44
- Revenue Growth
- CRDF 49.57
- FNWD 3.96
- 52 Week Low
- CRDF $1.30
- FNWD $22.82
- 52 Week High
- CRDF $6.42
- FNWD $33.50
- Technical
- Relative Strength Index (RSI)
- CRDF 72.82
- FNWD 42.42
- Support Level
- CRDF $3.06
- FNWD $30.56
- Resistance Level
- CRDF $5.64
- FNWD $31.16
- Average True Range (ATR)
- CRDF 0.45
- FNWD 0.29
- MACD
- CRDF 0.29
- FNWD -0.03
- Stochastic Oscillator
- CRDF 84.32
- FNWD 0.00
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About FNWD Finward Bancorp
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.